PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
OSL:PHO • NO0010000045
73.5 NOK
+9.4 (+14.66%)
Last: Mar 3, 2026, 10:04 AM
We assign a fundamental rating of 4 out of 10 to PHO. PHO was compared to 49 industry peers in the Pharmaceuticals industry. While PHO has a great health rating, there are worries on its profitability. PHO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- PHO had negative earnings in the past year.
- In the past year PHO had a positive cash flow from operations.
- PHO had negative earnings in 4 of the past 5 years.
- PHO had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -0.21%, PHO is doing worse than 63.27% of the companies in the same industry.
- With a Return On Equity value of -0.31%, PHO perfoms like the industry average, outperforming 40.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.21% | ||
| ROE | -0.31% | ||
| ROIC | N/A |
ROA(3y)-0.18%
ROA(5y)-2.89%
ROE(3y)-0.26%
ROE(5y)-4.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PHO has a Gross Margin of 92.11%. This is amongst the best in the industry. PHO outperforms 95.92% of its industry peers.
- PHO's Gross Margin has been stable in the last couple of years.
- PHO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.12% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.75%
GM growth 5Y-0.14%
2. Health
2.1 Basic Checks
- PHO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- PHO has less shares outstanding than it did 1 year ago.
- PHO has less shares outstanding than it did 5 years ago.
- PHO has a worse debt/assets ratio than last year.
2.2 Solvency
- PHO has an Altman-Z score of 5.86. This indicates that PHO is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of PHO (5.86) is better than 85.71% of its industry peers.
- The Debt to FCF ratio of PHO is 19.05, which is on the high side as it means it would take PHO, 19.05 years of fcf income to pay off all of its debts.
- PHO has a Debt to FCF ratio of 19.05. This is in the lower half of the industry: PHO underperforms 63.27% of its industry peers.
- PHO has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
- With a decent Debt to Equity ratio value of 0.21, PHO is doing good in the industry, outperforming 73.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 19.05 | ||
| Altman-Z | 5.86 |
ROIC/WACCN/A
WACC8.4%
2.3 Liquidity
- A Current Ratio of 3.64 indicates that PHO has no problem at all paying its short term obligations.
- With an excellent Current ratio value of 3.64, PHO belongs to the best of the industry, outperforming 93.88% of the companies in the same industry.
- A Quick Ratio of 3.22 indicates that PHO has no problem at all paying its short term obligations.
- PHO has a Quick ratio of 3.22. This is amongst the best in the industry. PHO outperforms 93.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.64 | ||
| Quick Ratio | 3.22 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 54.03% over the past year.
- Looking at the last year, PHO shows a small growth in Revenue. The Revenue has grown by 1.37% in the last year.
- Measured over the past years, PHO shows a quite strong growth in Revenue. The Revenue has been growing by 15.74% on average per year.
EPS 1Y (TTM)54.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.32%
Revenue 1Y (TTM)1.37%
Revenue growth 3Y10.65%
Revenue growth 5Y15.74%
Sales Q2Q%5.45%
3.2 Future
- Based on estimates for the next years, PHO will show a very strong growth in Earnings Per Share. The EPS will grow by 47.22% on average per year.
- The Revenue is expected to grow by 14.74% on average over the next years. This is quite good.
EPS Next Y-32.87%
EPS Next 2Y47.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.21%
Revenue Next 2Y10.82%
Revenue Next 3Y16.59%
Revenue Next 5Y14.74%
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- PHO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 74.51, the valuation of PHO can be described as expensive.
- PHO's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. PHO is more expensive than 71.43% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.11. PHO is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 74.51 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHO indicates a slightly more expensive valuation: PHO is more expensive than 69.39% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, PHO is valued a bit more expensive than the industry average as 65.31% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 379.46 | ||
| EV/EBITDA | 55.68 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as PHO's earnings are expected to grow with 47.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.22%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- PHO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
OSL:PHO (3/3/2026, 10:04:37 AM)
73.5
+9.4 (+14.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-18 2026-02-18/amc
Earnings (Next)05-07 2026-05-07
Inst Owners41.7%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap1.99B
Revenue(TTM)532.58M
Net Income(TTM)-1.52M
Analysts82.86
Price Target81.6 (11.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.02%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.47%
Revenue beat(4)2
Avg Revenue beat(4)-1.3%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)2.07%
Revenue beat(8)4
Avg Revenue beat(8)-1.81%
Revenue beat(12)6
Avg Revenue beat(12)-2.3%
Revenue beat(16)8
Avg Revenue beat(16)-2.79%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)5.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.1%
Revenue NY rev (3m)-1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 74.51 | ||
| P/S | 3.74 | ||
| P/FCF | 379.46 | ||
| P/OCF | 76.79 | ||
| P/B | 4.12 | ||
| P/tB | 7.64 | ||
| EV/EBITDA | 55.68 |
EPS(TTM)-0.06
EYN/A
EPS(NY)0.99
Fwd EY1.34%
FCF(TTM)0.19
FCFY0.26%
OCF(TTM)0.96
OCFY1.3%
SpS19.64
BVpS17.86
TBVpS9.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.21% | ||
| ROE | -0.31% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.12% | ||
| FCFM | 0.99% |
ROA(3y)-0.18%
ROA(5y)-2.89%
ROE(3y)-0.26%
ROE(5y)-4.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.75%
GM growth 5Y-0.14%
F-Score4
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 19.05 | ||
| Debt/EBITDA | 3.48 | ||
| Cap/Depr | 70.25% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 90.36% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.64 | ||
| Quick Ratio | 3.22 | ||
| Altman-Z | 5.86 |
F-Score4
WACC8.4%
ROIC/WACCN/A
Cap/Depr(3y)51.48%
Cap/Depr(5y)36.92%
Cap/Sales(3y)2.84%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.32%
EPS Next Y-32.87%
EPS Next 2Y47.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.37%
Revenue growth 3Y10.65%
Revenue growth 5Y15.74%
Sales Q2Q%5.45%
Revenue Next Year5.21%
Revenue Next 2Y10.82%
Revenue Next 3Y16.59%
Revenue Next 5Y14.74%
EBIT growth 1Y-103.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.59%
EBIT Next 3Y24.55%
EBIT Next 5YN/A
FCF growth 1Y-91.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.18%
OCF growth 3YN/A
OCF growth 5Y10.74%
PHOTOCURE ASA / PHO.OL FAQ
What is the fundamental rating for PHO stock?
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL.
What is the valuation status of PHOTOCURE ASA (PHO.OL) stock?
ChartMill assigns a valuation rating of 1 / 10 to PHOTOCURE ASA (PHO.OL). This can be considered as Overvalued.
Can you provide the profitability details for PHOTOCURE ASA?
PHOTOCURE ASA (PHO.OL) has a profitability rating of 2 / 10.
What is the financial health of PHOTOCURE ASA (PHO.OL) stock?
The financial health rating of PHOTOCURE ASA (PHO.OL) is 7 / 10.
Can you provide the expected EPS growth for PHO stock?
The Earnings per Share (EPS) of PHOTOCURE ASA (PHO.OL) is expected to decline by -32.87% in the next year.